Latest News
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
8 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that it has received European Commission approval for subcutaneous Sarclisa (isatuximab) for multiple myeloma across all existing indications cu...
Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide
8 June 2026 - Hangzhou Sciwind Biosciences Co Ltd, a China-based, commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, announced on Sunday that key data from a head-to-head stud...
Antengene presents first ATG-207 preclinical data at EULAR 2026
8 June 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Sunday that it has presented the first preclinical data on ATG-207, alpha masked and TGF beta RIII-biased CD3-TGF-beta bifunctional fusion protein i...
OriCell's GPC3 CAR-T Phase II hepatocellular carcinoma trial receives Chinese regulatory clearance
8 June 2026 - Chinese biotechnology company OriCell Therapeutics Holdings Limited announced on Sunday that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administra...
Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease
5 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) on Friday reported full results from the Phase III FIND-CKD trial evaluating Kerendia (finerenone) in adults with non-diabetic chronic kidney disease (nd-CK...